Dyadic International (NASDAQ:DYAI) Share Price Passes Above 50 Day Moving Average – Here’s What Happened

Dyadic International, Inc. (NASDAQ:DYAI) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.56 and traded as high as $1.99. Dyadic International shares last traded at $1.73, with a volume of 171,662 shares changing hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Dyadic International in a research report on Thursday, November 14th.

Dyadic International Stock Performance

The stock has a market capitalization of $51.04 million, a price-to-earnings ratio of -7.50 and a beta of 0.89. The company’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.39. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.54.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. The business had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter in the prior year, the business earned ($0.06) EPS. On average, equities research analysts expect that Dyadic International, Inc. will post -0.18 earnings per share for the current year.

Hedge Funds Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. grew its holdings in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 868,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the period. Chapin Davis Inc. owned about 2.97% of Dyadic International worth $903,000 at the end of the most recent quarter. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.